Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YTX-7739 tablet versus capsule relative bioavailability and food-effect study in healthy volunteers
NL-OMON50260Phase 1Active, not recruiting
- Sponsor
- Yumanity Therapeutics
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of YTX-7739 in Parkinson's disease (PD), sponsored by Yumanity Therapeutics. Primary endpoints: Relative bioavailability of tablet versus capsule, Pharmacokinetics of tablet formulation and 1 more. Started Jan 2022; status: active, not recruiting.
02
Drugs
YTX-7739
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON50260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50260.